Forgot Password?
Return to Course Listing

CME: Hereditary angioedema (HAE): Optimizing treatment strategies

ACCREDITATION EXPIRED: March 23, 2022

AN ACCREDITED UP-TO-DATE VERSION OF THIS TOPIC CAN BE FOUND AT:

Activity Description / Statement of Need:

In this online CME self-learning activity:

Hereditary angioedema (HAE) is a rare, debilitating, and potentially life-threatening disease due to C1-inhibitor (C1-INH) deficiency with an estimated frequency of 1 in 50,000 people. HAE is characterized by recurrent edema attacks and the cutaneous attacks can be disabling, with the skin, gastrointestinal tract, and upper airways are most commonly affected and with a persistent risk to the patient of acute events of laryngeal swelling that may prove fatal if not treated in a timely manner. Angioedema in general can be confused with cellulitis, Graves’ disease, blepharochalasis, eosinophilic fasciitis, or amyloidosis which can lead to delays in diagnosis, and inappropriate treatment poses the risk of adverse events, unnecessary surgical interventions, a higher burden of misery, and a potentially higher rate of morbidity and mortality.

Target Audience:

Healthcare professionals including: allergists, immunologists, and internists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in immunology; and any other HCPs who have an interest in or otherwise clinically encounter patients with HAE.

Commercial Support Disclosure: This activity is supported by an educational grant from Shire / Takeda.

Learners may participate in this activity free of charge.

Release Date: March 23, 2020 -- Expiration Date: March 23, 2022

Faculty: Jesse Pines, MD

Agenda

Faculty introduction, disclosures

Epidemiology, pathophysiology, and diagnosis of HAE

  • Burden of illness defined
  • Clinical presentation
  • Pathophysiology and triggers
  • Diagnosis
  • Patient case(s)

Pharmacotherapeutic management of HAE

  • Treatment concepts: long-term, short-term, and acute
  • Pharmacotherapies, present and emerging, and the literature behind them
  • Patient factors directing therapy
  • Adults vs. pediatrics
  • Route of administration, impact on quality of life
  • Barriers to care
  • Best practice: putting it all together
  • Patient case(s)

Summary, conclusions, and best practice recap
 
 
 

Learning Objectives

By the end of the session the participant will be able to:

  • Recall the pathophysiology of HAE such that it might inform treatment mechanisms.
  • Recognize the risks associated with misdiagnosis of HAE.
  • Evaluate a treatment plan for a patient with HAE designed to optimize safety and efficacy, suggesting modifications for improvement.
  • Describe present and emerging drug therapies for management of HAE and apply them to patient cases taking into account the patient’s history or anticipated place in therapy.

Accreditation

ACCME Activity #201861249

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Jesse Pines, MD, Professor of Emergency Medicine, Drexel University, has received financial compensation as a consultant from US Acute Care Solutions, NIH, HHS / ASPR funding; and advisor to CSL Bhring, Medtronic, Boeringer-Ingleheim, Nabriva, Beckman-Coulter, and Salix.
 
Disclosures of Peer Reviewer: Raffi Tachdjian, MD has received financial compensation as a consultant or speaker from Takeda, Pharming, CSL Behring and has received research grant support from  CSL Behring, Ionis, and Biocyst.
 
Disclosures of Peer Reviewer: R. Gentry Wilkerson, MD has received research grant support from  Roche, BMS, Cepheid, CoapTech, Janssen, Novartis, and Pfizer.
 
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
 
Commercial Support Disclosure: This activity is supported by an educational grant from Shire / Takeda.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Medical and nutritional management of eosinophilic esophagitis in adolescents and adults: Therapeutic updates and best practices

Systemic lupus erythematosus: Therapeutic updates and optimizing treatment

Employing biosimilars in the treatment of inflammatory health conditions: How to and should I?